Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 15 recruiting now early-phase tilt

Mitral Regurgitation: early-phase trial registry

15 of 27 indexed Mitral Regurgitation trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #598 of 28,707 conditions by registered trial count.

27 US clinical trials · 15 currently recruiting · #598 of 28,707 conditions by registered trial count

Mitral Regurgitation: 27 US clinical trials tracked, 15 recruiting.

Mitral Regurgitation is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Abbott Medical Devices, running 8 of these trials.

Enrollment posture brief

Registry condition mitral-regurgitation

OPEN 15 | RECR 56% | LATE 0 | EARLY 1 | RANK #598 | SPON 8

Nearest open-share peer: Acute Lymphoblastic Leukemia, Pediatric (56% recruiting · 9 trials)

Mitral Regurgitation (this)56%Alopecia Areata55.6%Acute Ischemic Stroke44.4%Adenocarcinoma25.9%Acne22.2%
Open-enrollment share among volume-matched conditions near Mitral Regurgitation

Mitral Regurgitation lists 15 open slots (56% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Mitral Regurgitation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Mitral Regurgitation is recruiting above its size-band peers.

    15 of 27 indexed trials (55.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Mitral Regurgitation research.

    Abbott Medical Devices accounts for 8 of 27 trials (29.6%). 17 distinct sponsors appear on at least one study for this condition label.

  3. Typical Mitral Regurgitation enrolment sits around 162 participants.

    Median target enrolment is 162 among the 27 trials that report a genuine target (sentinel values excluded). 11 of those (40.7%) plan for fewer than 100 participants.

  4. Mitral Regurgitation splits between interventional and observational designs.

    18 interventional and 9 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11

Open and recent trials

27 total, page 1 of 1

RECRUITING 1,000 participants

Abbott Cephea Mitral Valve Disease Registry

Abbott Medical Devices

NCT07069673

RECRUITING NA 900 participants

The ENCIRCLE Trial

Edwards Lifesciences

NCT04153292

RECRUITING 800 participants

CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry

Universitätsklinikum Hamburg-Eppendorf

NCT04688190

RECRUITING 550 participants

Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study

Abbott Medical Devices

NCT04761120

RECRUITING NA 450 participants

AltaValve Pivotal Trial

4C Medical Technologies

NCT06465745

RECRUITING NA 210 participants

The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

Mayra Guerrero

NCT04408430

RECRUITING 200 participants

Novel Characterization of Sex Specific Biologic Signatures in Valvular Heart Disease

The Cleveland Clinic

NCT06780241

RECRUITING NA 144 participants

Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock

Ottawa Heart Institute Research Corporation

NCT05298124

RECRUITING NA 60 participants

The CardioClip Study

Columbia University

NCT06241430

RECRUITING 50 participants

In Search of Best Practices for Patients With Heart Failure and Secondary Mitral Regurgitation: An Evaluation of the Inova Heart Failure Treatment Algorithm

Inova Health Care Services

NCT06675448

RECRUITING NA 50 participants

Cephea Early Feasibility Study

Abbott Medical Devices

NCT05061004

RECRUITING Phase 1 35 participants

Use of Phenylephrine for Assessment of Mitral Regurgitation Severity

Montefiore Medical Center

NCT04500899

RECRUITING NA 30 participants

An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System

HighLife SAS

NCT04029337

RECRUITING NA 25 participants

EFS of the CardioMech MVRS

CardioMech AS

NCT04820764

RECRUITING NA 25 participants

Evaluating Infrasonic Hemodynography

Scripps Health

NCT04636892

ACTIVE NOT RECRUITING 15,000 participants

Genomic Investigation of Cardiovascular Diseases

Scripps Translational Science Institute

NCT00722748

ACTIVE NOT RECRUITING NA 1,247 participants

Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

Edwards Lifesciences

NCT03706833

ACTIVE NOT RECRUITING 1,164 participants

MitraClip EXPAND G4 Study

Abbott Medical Devices

NCT04177394

ACTIVE NOT RECRUITING NA 103 participants

Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

Abbott Medical Devices

NCT03433274

ACTIVE NOT RECRUITING NA 72 participants

SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation

Edwards Lifesciences

NCT03230747

ACTIVE NOT RECRUITING NA 25 participants

Beating Heart Mitral Valve Repair With the HARPOON™ System

Edwards Lifesciences

NCT04375332

ACTIVE NOT RECRUITING NA 10 participants

Implantation of a Permanent Interatrial Shunt to Reduce Left Atrial Filling Pressures Following MitraClip

samir kapadia

NCT04729933

COMPLETED NA 2,118 participants

Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform

Tempus AI

NCT06099665

COMPLETED 1,145 participants

Development of an Algorithm to Differentiate Heart Murmurs Using Electronic Stethoscopes

Eko Devices

NCT04400513

COMPLETED 1,041 participants

The MitraClip® EXPAND Study of the Next Generation of MitraClip® Devices

Abbott Medical Devices

NCT03502811

COMPLETED NA 162 participants

Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional MR

Abbott Medical Devices

NCT07227675

COMPLETED NA 11 participants

Feasibility Study of the Tendyne Mitral Valve System in Mitral Annular Calcification

Abbott Medical Devices

NCT03539458

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Mitral Regurgitation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Tendyne Mitral Valve System Device
2 trials
Automated alert Behavioral
1 trials
MitraClip NTR/XTR System Device
1 trials
MitraClip® NT System Device
1 trials
Use of Eko CORE and Eko DUO electronic stethoscopes Device
1 trials
MitraClip G4 System Device
1 trials
Edwards SAPIEN M3 System Device
1 trials
V-Wave Shunt Placement Device
1 trials

US sites by state

Facility locations filed on Mitral Regurgitation trials. A trial with sites in several states counts in each.

California 17 trials
Minnesota 12 trials
New York 11 trials
Virginia 9 trials
Georgia 9 trials
Arizona 9 trials
Ohio 8 trials
North Carolina 8 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Mitral Regurgitation page

27 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mitral Regurgitation condition card totals 27 registered trials; most-linked intervention Tendyne Mitral Valve System; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.